Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters Definitive Agreement for ‘Transformative’ Acquisition of Leading Manufacturer of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has signed a definitive agreement to acquire BayMedica Inc., a private, U.S.-based company that specializes in the manufacturing and commercialization of rare cannabinoids. According to the announcement, the acquisition is expected to be final in the coming weeks, subject to standard closing conditions. The strategic move is designed to firmly establish INM as a leader in the manufacturing and commercialization of rare cannabinoids as well as strengthen the company’s position within growing consumer health and wellness cannabinoid markets. The acquisition includes BayMedica’s pipeline and several planned product launches, which will help InMed transition into a revenue-generating company. With the acquisition, InMed anticipates becoming a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches. The company anticipates that its proprietary cannabinoid manufacturing process, IntegraSyn(TM), combined with BayMedica’s synthetic biology and chemical synthesis capabilities, will provide flexibility to choose the most appropriate, cost-effective manufacturing method based on the cannabinoid and appropriate quality specifications for the desired market segment. “This is a transformative transaction for InMed,” said InMed president and CEO Eric A. Adams in the press release. “This acquisition gives us a breadth of synthetic cannabinoid manufacturing capabilities to deliver high-quality, cost-effective rare cannabinoids for any segment of the market from consumer packaged goods (CPG) to prescription pharmaceuticals. . . . This transaction transforms InMed into a revenue-generating company, providing tangible value for our shareholders. BayMedica has demonstrated a rapid increase in sales since initiating commercialization, and we expect to grow these revenues considerably in the short-to-medium term. We believe this segment of the industry is reaching an inflection point as commercial viability is being achieved as well as increased awareness and appreciation for bio-identical, synthetically produced cannabinoids.”

To view the full press release, visit

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”); the company is developing IntegraSyn(TM) to produce pharmaceutical-grade cannabinoids. INM is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based medicines. For more information, please visit  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in InMed Pharmaceuticals Inc. INM, MissionIRNewsBreaks. Bookmark the permalink.

Comments are closed.